Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 119, Suppl. 2, 2011
Issue release date: August 2011
Section title: UK Renal Registry. 13th Annual Report (December 2010)
Nephron Clin Pract 2011;119(suppl 2):c249–c254

Chapter 14: Enhancing Access to UK Renal Registry Data through Innovative Online Data Visualisations

Chaudhry A.a,b · Feest T.b
aCambridge University NHS Hospitals Foundation Trust, Cambridge, UK; bUK Renal Registry, Bristol, UK
email Corresponding Author

Afzal Chaudhry, UK Renal Registry, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK, Email: renalreg@renalreg.com

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Introduction: As the volume of data and analyses grows with time, so does the need to present this increasingly complex information in an accessible and clinically informative manner which is responsive to, and reflects the nature of, the enquiries made by those seeking to access the data. The UK Renal Registry interactive data portal: The UK Renal Registry (UKRR) now has a bespoke interactive data portal which provides a focussed point of access to a variety of graphical display formats and analyses of UKRR data including: – Centre-specific reports – a distillation of annual UKRR data including a colour-coded dashboard summary as well as both funnel plots and longitudinal statistical process control charts for a range of clinical parameters. – Interactive flash-based longitudinal Statistical Process Control charts on a per-centre and per-parameter basis allowing for a more detailed review of performance over time. These charts are the interactive correlates of those available in the centre-specific reports. – Rosling/Gapminder-style motion charts on a perparameter basis simultaneously detailing performance and activity data from multiple centres interactively over time (more details below). – An interactive graphical pivot chart solution using OLAP technology allowing users to design and export their own charts/analyses in real-time using UKRR data. Conclusion: This work builds strongly on the wealth of information arising from the high-quality validated UKRR datasets. The portal will empower and engage the UK renal community in the comparative analysis of delivered renal care ultimately leading to enhanced quality improvement over time.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of UK Renal Registry. 13th Annual Report (December 2010)

Published online: August 26, 2011
Issue release date: August 2011

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: (Print)
eISSN: 1660-2110 (Online)

For additional information: http://www.karger.com/NEC

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.